Patent classifications
A61K31/4162
1H-pyrazolo[4,3-b]pyridines as PDE1 inhibitors
The present invention provides 1H-pyrazolo[4,3-b]pyridin-7-amines of formula (1) as PDE1 inhibitors and their use as a medicament, in particular for the treatment of neurodegenerative disorders and psychiatric disorders. ##STR00001##
Substituted pyridines, pyridazines, pyrimidines, and 1,2,4-triazines as TYK2 inhibitors
Described herein are compounds of Formula (XVII) that are TYK2 inhibitors, methods of making such compounds, pharmaceutical compositions and medicaments comprising such compounds, and methods of Using such compounds in the treatment of conditions, diseases, or disorders that would benefit from modulation of TYK2 activity. ##STR00001##
Diaryl substituted 5,5-fused ring compounds as C5aR inhibitors
The present disclosure provides, inter alia, Compounds of Formula (I) ##STR00001##
or pharmaceutically acceptable salts thereof that are modulators of the C5a receptor. Also provided are pharmaceutical compositions and methods of use including the treatment of diseases or disorders involving pathologic activation from C5a and non-pharmaceutical applications.
Diaryl substituted 5,5-fused ring compounds as C5aR inhibitors
The present disclosure provides, inter alia, Compounds of Formula (I) ##STR00001##
or pharmaceutically acceptable salts thereof that are modulators of the C5a receptor. Also provided are pharmaceutical compositions and methods of use including the treatment of diseases or disorders involving pathologic activation from C5a and non-pharmaceutical applications.
Diaryl substituted 5,5-fused ring compounds as C5aR inhibitors
The present disclosure provides, inter alia, Compounds of Formula (I) ##STR00001##
or pharmaceutically acceptable salts thereof that are modulators of the C5a receptor. Also provided are pharmaceutical compositions and methods of use including the treatment of diseases or disorders involving pathologic activation from C5a and non-pharmaceutical applications.
TREATMENT COMPRISING FXR AGONISTS
The invention provides, FXR agonists for the treatment of a condition mediated by Farnesoid X receptor (FXR), in particular liver disease or intestinal disease, in a subject in need thereof, to reduce drug-induced adverse side effects inpatients suffering from such diseases or conditions.
TREATMENT COMPRISING FXR AGONISTS
The invention provides, FXR agonists for the treatment of a condition mediated by Farnesoid X receptor (FXR), in particular liver disease or intestinal disease, in a subject in need thereof, to reduce drug-induced adverse side effects inpatients suffering from such diseases or conditions.
NOVEL TREATMENT FOR WOLFRAM SYNDROME
The present invention is directed to a novel treatment for Wolfram Syndrome or heterozygous wolframin, to methods of treatment in order to delay, inhibit, ameliorate and/or reduce the likelihood of symptomology of a patient with Wolfram Syndrome or heterozygous wolframin.
NOVEL TREATMENT FOR WOLFRAM SYNDROME
The present invention is directed to a novel treatment for Wolfram Syndrome or heterozygous wolframin, to methods of treatment in order to delay, inhibit, ameliorate and/or reduce the likelihood of symptomology of a patient with Wolfram Syndrome or heterozygous wolframin.
Prodrugs of fused-bicyclic C5aR antagonists
The present disclosure provides, inter alia, Compounds of Formulae IA, IB, IC, IIA, IIB and IIC or pharmaceutically acceptable salts thereof that are modulators of the C5a receptor. Also provided are pharmaceutical compositions and methods of use including the treatment of diseases or disorders involving pathologic activation from C5a and non-pharmaceutical applications. ##STR00001## ##STR00002##